Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) hydrolyzes cGAMP within the tumor microenvironment (TME), suppressing stimulator of interferon genes (STING)-mediated antitumor immunity. Inspired by the phosphate-based inhibitor STF-1084, we developed a novel class of non-nucleotide ENPP1 inhibitors featuring a boronic acid zinc-binding group (ZBG), which led to the identification of the potent and pH-resilient compound 36. In vitro evaluations confirmed that compound 36 enhances cGAMP-mediated STING activation, driving the upregulation of key immune effectors and chemokines. Furthermore, in a syngeneic CT26 tumor model, monotherapy with compound 36 (20 mg/kg, IP) achieved a tumor growth inhibition (TGI) of 57.4%. Notably, combination therapy with a single dose of oxaliplatin (OX) exhibited a synergistic antitumor effect (TGI = 80.7%) without observable toxicity. Collectively, this study identifies compound 36 as a promising lead ENPP1 inhibitor and further highlights boronic acid as an effective ZBG for the development of ENPP1-targeted cancer immunotherapies.